Recent advancements in oral PCSK9 inhibitors have demonstrated promising efficacy in addressing lipid metabolism and hypercholesterolemia in clinical trials or preclinical studies [291,292]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.